These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 15500639

  • 1. Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity.
    Watanabe H, Mamelak AJ, Wang B, Howell BG, Freed I, Esche C, Nakayama M, Nagasaki G, Hicklin DJ, Kerbel RS, Sauder DN.
    Exp Dermatol; 2004 Nov; 13(11):671-81. PubMed ID: 15500639
    [Abstract] [Full Text] [Related]

  • 2. Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
    Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M.
    J Dermatol; 2007 Jul; 34(7):419-29. PubMed ID: 17584317
    [Abstract] [Full Text] [Related]

  • 3. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
    Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, Hicklin DJ, Kleinerman ES.
    Clin Cancer Res; 2007 Aug 15; 13(16):4867-73. PubMed ID: 17699866
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M.
    Clin Cancer Res; 2005 Jul 01; 11(13):4934-40. PubMed ID: 16000592
    [Abstract] [Full Text] [Related]

  • 5. Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus.
    Hervé MA, Meduri G, Petit FG, Domet TS, Lazennec G, Mourah S, Perrot-Applanat M.
    J Endocrinol; 2006 Jan 01; 188(1):91-9. PubMed ID: 16394178
    [Abstract] [Full Text] [Related]

  • 6. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
    Yoshiji H, Noguchi R, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Uemura M, Fukui H.
    Oncol Rep; 2005 May 01; 13(5):853-7. PubMed ID: 15809749
    [Abstract] [Full Text] [Related]

  • 7. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
    Camp ER, Yang A, Liu W, Fan F, Somcio R, Hicklin DJ, Ellis LM.
    Clin Cancer Res; 2006 Apr 15; 12(8):2628-33. PubMed ID: 16638876
    [Abstract] [Full Text] [Related]

  • 8. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.
    Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM, Weinerman A, Emmenegger U, Ma L, Thorpe P, Davidoff A, Huber J, Hicklin DJ, Kerbel RS.
    Cancer Res; 2004 Sep 15; 64(18):6616-25. PubMed ID: 15374976
    [Abstract] [Full Text] [Related]

  • 9. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
    Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH.
    Circ Res; 2007 Oct 26; 101(9):948-56. PubMed ID: 17823371
    [Abstract] [Full Text] [Related]

  • 10. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice.
    Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T, Fukui H.
    Hepatology; 2004 Jun 26; 39(6):1517-24. PubMed ID: 15185292
    [Abstract] [Full Text] [Related]

  • 11. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J, Huang S, Armstrong EA, Fowler JF, Harari PM.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1477-85. PubMed ID: 16029810
    [Abstract] [Full Text] [Related]

  • 12. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.
    Reichert F, Barak V, Tarshis M, Prindull G, Tarshis E, Ben-Ishay Z.
    Eur J Haematol; 2005 Jul 01; 75(1):41-6. PubMed ID: 15946309
    [Abstract] [Full Text] [Related]

  • 13. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE, Beck AW, Shivakumar L, Shih J, Fleming JB, Brekken RA.
    Ann Surg Oncol; 2006 Aug 01; 13(8):1145-55. PubMed ID: 16791450
    [Abstract] [Full Text] [Related]

  • 14. Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity.
    Fujiwara M, Muragaki Y, Ooshima A.
    Arch Dermatol Res; 2005 Oct 01; 297(4):161-9. PubMed ID: 16184401
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, Green JE.
    Oncogene; 2005 Jan 27; 24(5):790-800. PubMed ID: 15592523
    [Abstract] [Full Text] [Related]

  • 16. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants.
    Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE.
    Cancer Res; 2005 Feb 15; 65(4):1294-305. PubMed ID: 15735015
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
    Sini P, Samarzija I, Baffert F, Littlewood-Evans A, Schnell C, Theuer A, Christian S, Boos A, Hess-Stumpp H, Foekens JA, Setyono-Han B, Wood J, Hynes NE.
    Cancer Res; 2008 Mar 01; 68(5):1581-92. PubMed ID: 18316624
    [Abstract] [Full Text] [Related]

  • 18. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
    Pala L, Cresci B, Manuelli C, Maggi E, Yamaguchi YF, Cappugi P, Rotella CM, Giannini S.
    Microvasc Res; 2005 Nov 01; 70(3):179-88. PubMed ID: 16271941
    [Abstract] [Full Text] [Related]

  • 19. Endothelial cell response to lactate: implication of PAR modification of VEGF.
    Kumar VB, Viji RI, Kiran MS, Sudhakaran PR.
    J Cell Physiol; 2007 May 01; 211(2):477-85. PubMed ID: 17167776
    [Abstract] [Full Text] [Related]

  • 20. Reduced 2,4-dinitro-1-fluorobenzene-induced contact hypersensitivity response in IL-15 receptor alpha-deficient mice correlates with diminished CCL5/RANTES and CXCL10/IP-10 expression.
    Chen JP, Liao NS, Lai SL, Hsu L, Mao WY, Ku MC, Liao F.
    Eur J Immunol; 2005 Mar 01; 35(3):690-8. PubMed ID: 15719370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.